Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Instil Bio (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) announced they will co-host an investor and analyst breakfast event in Chicago on May 31, 2025. The event, scheduled from 8:00 to 9:30 am CT near McCormick Convention Center, will feature company management and a key opinion leader in immuno-oncology. They will discuss the PD-(L)1xVEGF bispecific antibody landscape and provide clinical trial updates. Interested investors and analysts can register by emailing investorrelations@instilbio.com.
Instil Bio (Nasdaq: TIL) e ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) hanno annunciato che co-organizzeranno un evento colazione per investitori e analisti a Chicago il 31 maggio 2025. L'evento, previsto dalle 8:00 alle 9:30 ora centrale, si terrà nei pressi del McCormick Convention Center e vedrà la partecipazione del management delle aziende e di un esperto di rilievo nel campo dell'immuno-oncologia. Verranno discussi il panorama degli anticorpi bispecifici PD-(L)1xVEGF e aggiornamenti sui trial clinici. Gli investitori e analisti interessati possono registrarsi scrivendo a investorrelations@instilbio.com.
Instil Bio (Nasdaq: TIL) y ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) anunciaron que coorganizarán un desayuno para inversores y analistas en Chicago el 31 de mayo de 2025. El evento, programado de 8:00 a 9:30 am CT cerca del McCormick Convention Center, contará con la presencia de la dirección de las compañías y un líder de opinión clave en inmuno-oncología. Se discutirán el panorama de anticuerpos bispecíficos PD-(L)1xVEGF y se proporcionarán actualizaciones sobre ensayos clínicos. Los inversores y analistas interesados pueden registrarse enviando un correo a investorrelations@instilbio.com.
Instil Bio (나스닥: TIL)과 ImmuneOnco Biopharmaceuticals (홍콩증권거래소: 1541.HK)는 2025년 5월 31일 시카고에서 투자자 및 애널리스트 조찬 행사를 공동 개최한다고 발표했습니다. 이 행사는 오전 8시부터 9시 30분까지 CT 시간으로 McCormick 컨벤션 센터 인근에서 열리며, 회사 경영진과 면역종양학 분야의 주요 의견 리더가 참석할 예정입니다. PD-(L)1xVEGF 이중특이항체 분야와 임상시험 최신 정보를 논의할 예정입니다. 관심 있는 투자자와 애널리스트는 investorrelations@instilbio.com으로 등록할 수 있습니다.
Instil Bio (Nasdaq : TIL) et ImmuneOnco Biopharmaceuticals (HKEX : 1541.HK) ont annoncé qu'ils co-organiseront un petit-déjeuner pour investisseurs et analystes à Chicago le 31 mai 2025. L'événement, prévu de 8h00 à 9h30 heure centrale, se tiendra près du McCormick Convention Center et réunira la direction des entreprises ainsi qu'un expert reconnu en immuno-oncologie. Ils aborderont le paysage des anticorps bispécifiques PD-(L)1xVEGF et fourniront des mises à jour sur les essais cliniques. Les investisseurs et analystes intéressés peuvent s'inscrire en envoyant un courriel à investorrelations@instilbio.com.
Instil Bio (Nasdaq: TIL) und ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) haben angekündigt, dass sie am 31. Mai 2025 ein gemeinsames Frühstücksevent für Investoren und Analysten in Chicago veranstalten werden. Die Veranstaltung findet von 8:00 bis 9:30 Uhr CT in der Nähe des McCormick Convention Centers statt und umfasst das Management der Unternehmen sowie einen führenden Experten im Bereich Immunonkologie. Es werden die Entwicklungen im Bereich der PD-(L)1xVEGF bispezifischen Antikörper sowie Updates zu klinischen Studien vorgestellt. Interessierte Investoren und Analysten können sich per E-Mail an investorrelations@instilbio.com anmelden.
- None.
- None.
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center.
Instil and ImmuneOnco management, along with a key opinion leader in the field of immuno-oncology, will discuss the evolving PD-(L)1xVEGF bispecific antibody landscape and recent clinical trial updates from Instil and ImmuneOnco.
Investors and analysts interested in attending should register by emailing their contact information to reserve seating to investorrelations@instilbio.com.
About ImmuneOnco
ImmuneOnco is a clinical-stage biotech company focused on discovery and development of biologics to treat cancers, autoimmune diseases and metabolic diseases. With 10+ assets all originated in-house and the most advanced asset in phase III right now, ImmuneOnco is pursuing innovative therapies to improve patients’ health. For more information visit www.immuneonco.com.
About Instil Bio
Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information, visit www.instilbio.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com
FAQ
When and where is Instil Bio (TIL) hosting its investor breakfast during ASCO 2025?
What topics will be discussed at the Instil Bio (TIL) ASCO 2025 investor event?
How can investors register for Instil Bio's ASCO 2025 breakfast meeting?
Who will be presenting at the Instil Bio (TIL) ASCO 2025 investor breakfast?
